Pioneering Cancer Treatment Breakthroughs: Invion's (ASX:IVX) Thian Chew discusses the Promise of Photosoft Technology and Upcoming Clinical Trials

ASX BRIEFS

Unlock the potential of groundbreaking cancer treatments with Thian Chew, CEO of Invion, as he unveils the transformative power of Photosoft technology in our latest podcast. Discover how this revolutionary approach is meticulously designed to target and obliterate cancer cells while sparing the healthy ones. In this engaging session, Thian navigates us through Invion's journey from meticulous preclinical research to the pivotal moment of human trials, sharing the exhilaration of placing their innovations under the real-world microscope.
Thian not only sheds light on the intricacies of Photosoft technology but also takes us behind the scenes of Invion's strategic partnerships with leading research institutions, including the Hudson Institute of Medical Research and the Peter McCallum Cancer Centre. These alliances are not just endorsements of the promising tech; they're propelling Invion's mission with pivotal financial support. Get an insider look at the upcoming clinical trials poised to make waves in the treatment of non-melanoma skin cancer, inogenital cancers, and a yet-to-be-named solid tumor with substantial medical needs. This episode isn't just a conversation; it's a glimpse into a future where cancer may no longer be an invincible foe.